GW&K Investment Management LLC lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 32.8% during the third quarter, Holdings Channel reports. The fund owned 2,827,884 shares of the medical research company’s stock after acquiring an additional 698,463 shares during the period. GW&K Investment Management LLC’s holdings in NeoGenomics were worth $51,920,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in NeoGenomics by 30.1% in the third quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 644 shares during the period. Farther Finance Advisors LLC grew its stake in NeoGenomics by 117.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,701 shares of the medical research company’s stock worth $31,000 after purchasing an additional 917 shares in the last quarter. Root Financial Partners LLC acquired a new position in NeoGenomics during the 3rd quarter worth $29,000. Jacobi Capital Management LLC purchased a new stake in NeoGenomics during the 3rd quarter worth about $37,000. Finally, Allworth Financial LP increased its holdings in NeoGenomics by 110.4% during the 2nd quarter. Allworth Financial LP now owns 4,132 shares of the medical research company’s stock worth $60,000 after purchasing an additional 2,168 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on NEO shares. Wall Street Zen raised NeoGenomics from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Needham & Company LLC lifted their price objective on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. BTIG Research reissued a “buy” rating and set a $28.00 price objective on shares of NeoGenomics in a research report on Thursday, October 29th. Piper Sandler restated an “overweight” rating on shares of NeoGenomics in a research note on Wednesday, October 7th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.88.
View Our Latest Stock Report on NEO
NeoGenomics Price Performance
NeoGenomics stock opened at $15.09 on Friday. The company has a quick ratio of 3.31, a current ratio of 3.53 and a debt-to-equity ratio of 0.47. The company has a fifty day simple moving average of $17.37 and a 200-day simple moving average of $13.08. NeoGenomics, Inc. has a 12-month low of $7.07 and a 12-month high of $20.15.
NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its earnings results on Wednesday, October 28th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. NeoGenomics had a negative return on equity of 0.99% and a negative net margin of 4.10%. The firm had revenue of $209.25 million for the quarter, compared to analyst estimates of $206.70 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. NeoGenomics’s revenue for the quarter was up 11.3% compared to the same quarter last year. Research analysts expect that NeoGenomics, Inc. will post -0.06 EPS for the current year.
NeoGenomics Profile
NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.
See Also
- Five stocks we like better than NeoGenomics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Free Report).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
